Combination of radiotherapy with EGFR antagonists for head and neck carcinoma

No abstract is available for this paper.

• Publication year

  2007

• Venue

  International Journal of Clinical Oncology

• Publication date

  2007-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10147-006-0663-5PMID 17443277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• What did we learn?

  2022cited by this paper
• Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation.

  2007cited by this paper
• Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

  2006cited by this paper
• Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma.

  2006cited by this paper
• Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy

  2006cited by this paper
• Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.

  2006cited by this paper
• VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.

  2006cited by this paper
• A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

  2006cited by this paper
• Cancer Statistics, 2006

  2006cited by this paper
• Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.

  2006cited by this paper
• Antitumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.

  2006cited by this paper
• Clinical, signaling pathway, and cellular effects of epidermal growth factor receptor (EGFR) inhibition with gefitinib in combination with paclitaxel and radiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

  2006cited by this paper
• Phase II clinical trial preliminary report: Cetuximab, gemcitabine and simultaneous radiotherapy for locally advanced head and neck cancer: Preliminary report.

  2006cited by this paper
• Epidermal growth factor receptor directed therapy in head and neck cancer.

  2006cited by this paper
• Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival

  2006cited by this paper
• Epidermal growth factor receptor biology in head and neck cancer.

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

  2006cited by this paper
• Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN).

  2006cited by this paper
• Signaling through ERBB receptors: multiple layers of diversity and control.

  2006cited by this paper
• Radiation combined with EGFR signal inhibitors: head and neck cancer focus.

  2006cited by this paper
• Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

  2006cited by this paper
• Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

  2006cited by this paper
• A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial

  2006cited by this paper
• Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: A phase I/II trial of the Minnie Pearl Cancer Research Network.

  2006cited by this paper
• Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  2006cited by this paper
• A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors

  2006cited by this paper
• Co‐regulation of B‐Myb expression by E2F1 and EGF receptor

  2006cited by this paper
• Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region

  2006cited by this paper
• Phosphotyrosine interactome of the ErbB-receptor kinase family

  2005cited by this paper
• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  2005cited by this paper
• Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase*

  2005cited by this paper
• GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways

  2005cited by this paper
• Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

  2005cited by this paper
• Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis

  2005cited by this paper
• Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.

  2005cited by this paper
• Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

  2005cited by this paper
• Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

  2005cited by this paper
• Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients.

  2005cited by this paper
• Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.

  2005cited by this paper
• Repopulation of cancer cells during therapy: an important cause of treatment failure

  2005cited by this paper
• Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.

  2005cited by this paper
• ZD6474 – clinical experience to date

  2005cited by this paper
• Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx

  2005cited by this paper
• Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

  2005cited by this paper
• Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• Prostaglandin E2 and Bradykinin contribute to head and neck squamous cell carcinoma carcinogenesis via EGFR dependent and independent mechanisms.

  2005cited by this paper
• Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.

  2005cited by this paper
• Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)

  2005cited by this paper
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?

  2005cited by this paper
• Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.

  2005cited by this paper
• Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma

  2005cited by this paper
• Early Phase I Data on an Irreversible Pan-Er Inhibitor: CI-1033. What Did We Learn?

  2004cited by this paper
• Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

  2004cited by this paper
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)

  2004cited by this paper
• Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)

  2004cited by this paper
• Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy

  2004cited by this paper
• Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results.

  2004cited by this paper
• Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy.

  2004cited by this paper
• Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade

  2004cited by this paper
• ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy

  2004cited by this paper
• AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

  2004cited by this paper
• Phosphorylation of Y845 on the Epidermal Growth Factor Receptor Mediates Binding to the Mitochondrial Protein Cytochrome c Oxidase Subunit II

  2004cited by this paper
• Epidermal Growth Factor Receptor Inhibition in Cancer Therapy: Biology, Rationale and Preliminary Clinical Results

  2004cited by this paper
• The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck.

  2004cited by this paper
• The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.

  2004cited by this paper
• Phosphatidylinositide 3-kinase/AKT in radiation responses.

  2004cited by this paper
• Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo

  2004cited by this paper
• ERBB receptor tyrosine kinases and cellular radiation responses

  2003cited by this paper
• Trafficking of the ErbB receptors and its influence on signaling.

  2003cited by this paper
• EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.

  2003cited by this paper
• Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

  2003cited by this paper
• Epidermal Growth Factor Receptor-stimulated Activation of Phospholipase Cγ-1 Promotes Invasion of Head and Neck Squamous Cell Carcinoma

  2003cited by this paper
• Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

  2003cited by this paper
• The epidermal growth factor receptor mediates radioresistance.

  2003cited by this paper
• Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.

  2003cited by this paper
• An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

  2003cited by this paper
• Constitutive activation of Stat5b contributes to carcinogenesis in vivo.

  2003cited by this paper
• EGFRvIII-mediated radioresistance through a strong cytoprotective response

  2003cited by this paper
• The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.

  2003cited by this paper
• Small-molecule tyrosine kinase inhibitors as radiosensitizers.

  2002cited by this paper
• Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas.

  2002cited by this paper
• Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).

  2002cited by this paper
• Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

  2002cited by this paper
• Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.

  2002cited by this paper
• Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor*

  2002cited by this paper
• ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

  2002cited by this paper
• Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation.

  2002cited by this paper
• Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines*

  2002cited by this paper
• Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade.

  2002cited by this paper
• STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo.

  2002cited by this paper

• Epidermal growth factor receptor activity is elevated in glioma cancer stem cells and is required to maintain chemotherapy and radiation resistance

  2017cites this paper
• Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma

  2014cites this paper
• Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: A pilot study

  2014cites this paper
• Molecular Targeting Drugs for Head and Neck Cancer: EGFR Signaling and its Crosstalk

  2013cites this paper
• Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma

  2012cites this paper
• Cetuximab for head and neck cancer: From bench to clinic

  2012cites this paper
• Studies on the inhibition of feline EGFR in squamous cell carcinoma: Enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors

  2011influential citation
• Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways

  2011cites this paper
• Enhanced Sensitivity to Gefitinib after Radiation in Non-Small Cell Lung Cancer Cells

  2011cites this paper
• Epidermal growth factor receptor as a therapeutic target in veterinary oncology.

  2011cites this paper
• Nuclear localization of Nm23‐H1 in head and neck squamous cell carcinoma is associated with radiation resistance

  2011cites this paper
• Differential proteomics in the search for biomarkers of radiotherapy resistance

  2011cites this paper
• EGFR Signaling and Radiation

  2011cites this paper
• MicroRNAs in Predicting Radiotherapy and Chemotherapy Response

  2011cites this paper
• Effects and Therapeutic Potential of Targeting Dysregulated Signaling Axes in Squamous Cell Carcinoma: Another Kinase of Transcription and Mammalian Target of Rapamycin

  2011cites this paper
• Molecular Determinants of Radiation Response

  2011cites this paper
• Do NSCLC patients become sensitive to second-line erlotinib treatment after previous radiotherapy? Czy pierwszorzutowa radioterapia może uwrażliwiać chorych z niedrobnokomórkowym rakiem płuca na erlotynib stosowany w drugiej linii leczenia?

  2010cites this paper
• Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6

  2010cites this paper
• MiRNA profiling of tumor-derived exosomes

  2010cites this paper
• The role of apoptosis in radiation oncology

  2009cites this paper
• Activated epidermal growth factor receptor in ovarian cancer.

  2009cites this paper
• Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel.

  2009cites this paper
• Increase in thiol oxidative stress via glutathione reductase inhibition as a novel approach to enhance cancer sensitivity to X-ray irradiation.

  2009cites this paper
• Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma

  2009cites this paper
• Cetuximab for Head and Neck Cancer

  2008cites this paper
• ErbB antagonists patenting: "playing chess with cancer".

  2008cites this paper
• Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells

  2008influential citation
• Should there be more molecular staging of head and neck cancer to improve the choice of treatments and thereby improve survival?

  2008cites this paper
• Tumormarker und Biomarker bei Hals-Kopf-Tumoren

  2008cites this paper